Research Article

Synthetic Peptides as Structural Maquettes of Angiotensin-I Converting Enzyme Catalytic Sites

Zinovia Spyranti,¹ Athanassios S. Galanis,¹ George Pairas,¹ Georgios A. Spyroulias,¹ Evy Manessi-Zoupa,² and Paul Cordopatis¹

¹ Department of Pharmacy, University of Patras, GR-26504, Patras, Greece

² Department of Chemistry, University of Patras, GR-26504, Patras, Greece

Correspondence should be addressed to Georgios A. Spyroulias, g.a.spyroulias@upatras.gr and Paul Cordopatis, pacord@upatras.gr

Received 15 January 2010; Accepted 16 March 2010

Academic Editor: Spyros Perlepes

Copyright © 2010 Zinovia Spyranti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The rational design of synthetic peptides is proposed as an efficient strategy for the structural investigation of crucial protein domains difficult to be produced. Only after half a century since the function of ACE was first reported, was its crystal structure solved. The main obstacle to be overcome for the determination of the high resolution structure was the crystallization of the highly hydrophobic transmembrane domain. Following our previous work, synthetic peptides and Zinc(II) metal ions are used to build structural maquettes of the two Zn-catalytic active sites of the ACE somatic isoform. Structural investigations of the synthetic peptides, representing the two different somatic isoform active sites, through circular dichroism and NMR experiments are reported.

1. Introduction

Angiotensin Converting Enzyme (ACE) catalyses the conversion of angiotensin-I (AI) to the vasoconstrictor angiotensin-II (AII) [1] and inactivates the vasodilatory peptide bradykinin by removing C-terminal dipeptides [2]. The inhibition of ACE enzymatic activity against AI was considered as one of the major challenges against hypertensive disease and congestive heart failure [3]. Over the past 20 years, ACE inhibitors have presented significant cardioprotective and vasculoprotective activity, by reducing oxidative stress and inflammation in the endothelium. Moreover, ACE inhibitors have been effective in improving blood flow and flow-mediated vasodilation. Inhibition of the angiotensin converting enzyme significantly reduces cardiovascular risk in a broad range of high-risk patients [4, 5].

ACE is a Zinc Metallopeptidase and one of the major components of the Renin-Angiotensin System (RAS) that regulates blood pressure [6–8]. In human, ACE is expressed as a somatic isoform in endothelial, epithelial, and neuroepithelial cells and as a smaller isoform only in male

germinal cells. Somatic ACE (1306 AA, 150 kDa) consists of two homologous domains, one at each terminal, containing zinc catalytic sites (N- and C-zinc catalytic sites) [9]. The testis isoform is composed of 732 residues (83 kDa) with the 665-residue C-terminal domain being identical to the C-terminal domain of the somatic form [10–13]. Both isoforms possess a zinc-binding domain, with the somatic isoform containing one additional high homology active site (N-catalytic site). ACE active sites possess the characteristic HEXXH Zn-binding motif (the two His comprise the first two Zn-ligands) and falls into the gluzincin family [14]. The third Zn ligand, glutamic acid, is sited 23 residues towards the enzyme C-terminal at the second characteristic sequence EAXGD [15]. The fourth zinc ligand is a water molecule.

In subsequent to our previous work [16, 17], novel synthetic peptides have been investigated as structural maquettes, in order to shed further light on the conformational characteristics of both somatic isoform catalytic site domains.

Design, peptide synthesis, and a thorough investigation of the optimal conditions in order to mimic as closely

Pep.	ACE _N (37)	1.HEMGHIQYY	11.YKDLPVSL	21.GANPGFHE	31IGDV.37
ACE _N	domain	HHEMGHIQYY	LQYKDLFSL	RREGANPGFHE	AIGDVL
sACE *		360.EMGHIQYY	370.YKDLPVSL	380.GANPGFHE	390GDV.396

Pep.	ACE _C (37)	1.HEMGHIQYF	11.YKDLPVAL	21.EGANPGFHE	31IGDV.37
ACE _C	domain	HHEMGHIQYF	MQYKDLPVALL	REGANPGFHE	AIGDVL
sACE		958.EMGHIQYF	968.YKDLPVAL	978.GANPGFHE	988GDV.994
tACE	x-ray	382.EMGHIQYF	392.YKDLPVAL	402.GANPGFHE	412GDV.418

FIGURE 1: Synthetic peptide maquettes of the N- and C- active site domains of human somatic ACE (sACE). Sequence numbering of peptides, sACE, testis isoform (tACE) and crystal structures domains. The different residues among the two sequences are highlighted.

FIGURE 2: (a) Short-, medium-, and long-range connectivities. (b) Number of NOE constraints per residue (white, gray, dark gray, and black vertical bars represent, resp., intraresidue, sequential, medium-range and long-range connectivities). (c) Schematic representation of the sequential and medium range NOEs involving HN, H α , and H β protons for Zn²⁺-ACE_N(37) (corresponds to His³⁶⁰-Ala³⁹⁶ of the human somatic form).

as possible the structure of the enzyme native active sites are reported. The peptide structures have been determined through circular dichroism and NMR experiments.

The conformational differences of the peptide maquettes representing the two sACE active sites have been also investigated. Moreover, the NMR solution structures of the peptides are being compared to the crystal structure of somatic ACE_N active site [18] and the testis ACE isoform (tACE) [19] that corresponds to the somatic ACE_C domain.

In general, we report herein a work, which exploits the potential of peptide chemistry to synthesize polypeptides that represent protein domains or functional fragments and applies a step-by-step investigation strategy able to extract crucial structural data, especially for the metal active sites of enzymes/proteins or others biopolymers, whose biological expression and crystallization are difficult to be acquired, such as GPCRs and highly hydrophobic transmembrane proteins.

FIGURE 3: (a) Short-, medium-, and long-range connectivities. (b) Number of NOE constraints per residue (white, gray, dark gray, and black vertical bars represent, resp., intramolecular, sequential, medium-range, and long-range connectivities). (c) Schematic representation of the sequential and medium range NOEs involving HN, H α , and H β protons for Zn²⁺-ACE_C(37) (corresponds to His⁹⁵⁸-Ala⁹⁹⁴ of the human somatic form).

2. Materials and Methods

2.1. Peptide Synthesis. Both peptides representing the domains of the two somatic ACE (sACE) active sites ACE_N(37): sACE(360–396); ACE_C(37): sACE(958–994) were synthesized on solid support by Fmoc/tBu chemistry, as previously described [15]. Sequence enumeration of the synthetic peptides and the corresponding domains of the human somatic isoform as well as the numbering of the C- (tACE) and N-domain (ACE_N) crystal structures are shown in Figure 1.

2.2. Circular Dichroism Experiments. CD experiments were acquired for both ACE_N(37) and ACE_C(37) peptides, monitoring the effect of different trifluoroethanol (TFE) concentration, pH values, and Zn²⁺ addition on their conformations. Spectra were recorded on a Jasco 710 spectropolarimeter using quartz cells of 1.0 cm and 0.5 cm path length, in the far-UV (200 nm–260 nm) at a scanning rate of 100 nm/min, a time constant of 1 s, and a bandwidth of 1 nm. Spectral resolution was 0.2 nm, and 4 scans were averaged per spectrum.

The concentration used for each sample was 0.3–0.35 mg/ml of pure peptide in a buffer of 50 mM Tris-HCl

and 200 mM NaCl. The effect of TFE on the peptide conformation was monitored for 0%–100% TFE (v/v), 25°C, and pH = 7.0. Spectra of different pH values ranging from 2.6 to 7.0 were recorded for the Zn-containing ACE_N(37) peptide, at 65% TFE and 25°C. Quantitative evaluation of secondary structure according to the CD data was calculated using the CDNN CD Spectra Deconvolution Program obtained from <http://bioinformatik.biochemtech.unihalle.de/cdnn/> [20]. The CD spectra are reported in molar ellipticity as mdeg $\times$ cm²/dmol according to molecular masses and peptide length.

2.3. Nuclear Magnetic Resonance Experiments. 5 mg of peptide samples were dissolved in a mixture of 65% TFE in H₂O, containing 50 mM Tris buffer and 200 mM NaCl. ZnCl₂ was added in a slight excess of the peptide equivalents (1:1.1) until 0.5 ml final sample volume, with the peptide concentration being approximately 2 mM at pH value 4.9–5.1.

Data were acquired at 298 K on a Bruker Avance 600 MHz spectrometer. ¹H 1D NMR spectra were recorded using spectral width of 12–17 ppm with or without presaturation of the H₂O signal. ¹H-¹H 2D TOCSY [21, 22] were recorded using the MLEV-17 spin lock sequence using τ_m = 80 ms.

FIGURE 4: Circular dichroism spectra (left) and corresponding diagrams (right) of helical content through data analysis by CDNN software of (a) 2,2,2-trifluoroethanol (TFE) range from 0% to 100% of Zn^{2+} -ACE_N(37) samples, at pH = 5.0, $T = 25^\circ\text{C}$, 50 mM Tris-HCl, and 200 mM NaCl and (b) of pH range from 2.6 to 7 of Zn^{2+} -ACE_N(37) samples, at 65% TFE, $T = 25^\circ\text{C}$, 50 mM Tris-HCl, and 200 mM NaCl.

^{15}N HSQC and ^{13}C HSQC spectra [23, 24] have been recorded at 500 MHz equipped with cryoprobe for $^{15}\text{N}/^{13}\text{C}$ nuclei in natural abundance. ^1H - ^1H TPPI NOESY [25, 26] spectra were acquired using mixing time $\tau_m = 200$ ms applying water suppression during the relaxation delay and mixing time. For data processing and spectral analysis, the standard Bruker software (XWIN-NMR 3.5) and XEASY program [27] (ETH, Zurich) were used.

1318 and 1578 NOESY cross-peaks were assigned in both dimensions for ACE_C(37), and ACE_N(37), respectively, in TFE aqueous solution (TFE/H₂O 2:1). The number of unique cross-peaks was 753 and 773 for ACE_C(37) and ACE_N(37), respectively. Their intensities were converted into upper limit distances through CALIBA [28]. The NOE-

derived structural information extracted from the analysis of NOESY spectra acquired in aqueous TFE solutions under identical experimental conditions for both peptides were introduced to DYANA [29, 30] software for structure calculation (Figures 2 and 3). Structural calculations have been performed on IBM RISC6000 and xw4100/xw4200 HP Linux workstations. The family ensemble of Zn^{2+} -ACE_N(37) peptide presents root mean square deviation (RMSD) values of $0.65 \pm 0.21 \text{ \AA}$ and $1.25 \pm 0.24 \text{ \AA}$ for backbone and heavy atoms, respectively, and the average target function was found to be $0.39 \pm 0.0164 \text{ \AA}^2$. The RMSD values of the Zn^{2+} -ACE_C(37) peptide were $0.55 \pm 0.23 \text{ \AA}$ and $1.04 \pm 0.27 \text{ \AA}$ for backbone and heavy atoms, respectively, and target function lies in the range $0.60 \pm 4.78 \times 10^{-2} \text{ \AA}^2$.

FIGURE 5: Fingerprint regions of 600 MHz TOCSY ((a) ACE_C(37) and (b) ACE_N(37)) and NOESY ((c) ACE_C(37) and (d) ACE_N(37)) spectra recorded at $T = 298$ K. The sequential connectivity pattern shown indicates the peptide sequence-specific resonance assignment.

3. Results and Discussion

3.1. α -Helix Content Measurements through Circular Dichroism Data. The Circular Dichroism (CD) experiments provided a qualitative determination of the peptide secondary structure elements in different TFE concentrations, pH values, and metal addition, leading to the determination of high resolution experimental conditions (Figure 4).

Specifically, the Zn²⁺-ACE_N(37) peptide presents an unfolded structure with low α -helical content in aqueous solution. Low TFE concentrations (up to 20%) do not seem to have major effect on the peptide conformation (Figure 4(a)). However, the CD spectrum of the sample containing 35% TFE shows two intense minima at 208 and 220 nm, characteristics of α -helical structure. Thus, for TFE concentration ranging from 20% to 35%, an abrupt structural change takes place, leading to a dramatical increase of α -helix content from 26% to 52%. At higher TFE concentrations (50%–100%), no remarkable alteration of the helical content is noticed. In more detail, the α -helical content is increased from 54% to 60%, for TFE

concentration increasing from 50% to 100%, indicating secondary structure stability of the Zn²⁺-ACE_N(37) peptide at alcohol concentration greater than 50%. Similar results were obtained for the Zn²⁺-ACE_C(37) peptide (data not shown). As a conclusion, the synthetic peptides exhibit a remarkable tendency to adopt helical conformation.

In order to investigate the pH effect on the α -helical content of the Zn²⁺-ACE_N(37) peptide, CD measurements were performed in 65% of TFE at 25°C, at acidic, low acidic, and neutral pH values. Spectra representing two sets of pH values nearly overlap, thus suggesting that the secondary structure of ACE peptides exhibit minor differences at these pH values (Figure 4(b)). In particular, at acidic (pH 2.6) and mild acidic (pH 4.0) conditions, the Zn-containing ACE_N(37) solutions possess approximately 48% α -helical content while at pH values of 5.0 and 7.0, the helicity of the ACE_N(37) in the presence of Zn²⁺ ions is found to be approximately 57.0%.

3.2. NMR Spectra Assignment of Zn²⁺-ACE_N(37) and Zn²⁺-ACE_C(37) Peptides. Thirty-six out of 37 residues of the

TABLE 1: ^1H , ^{15}N , and ^{13}C chemical shifts (ppm) of the residues in the Zn^{2+} -ACE_N(37) peptide at 298K ($\text{H}_2\text{O}/\text{TFE}$ -d2 34%/66% v/v. pH = 4.9).

Residue	HN/N	H α /C α	H β /C β	Other
1	His	4.45 55.39		H δ 2 7.30; H ϵ 18.44 Cδ 120.02 Cϵ1 139.44
2	His	7.99 N 117.01	3.38/3.29 28.45	H δ 2 7.32; H ϵ 1 8.45 Cδ2 120.05 Cϵ1 137.64
3	Glu	8.45 N 121.15	2.15/2.14 31.91	γCH_3 2.65/2.62 Cγ 31.90
4	Met	4.35 57.51	2.13/2.09 33.70	H γ 2.49/2.44 Cγ 34.78
5	Gly	8.22 N 109.59	3.98 45.79	
6	His	8.22 N. 119.31	4.72 57.08	3.41/3.39 28.57
7	Ile	8.11 N 122.73	4.05 64.30	H δ 2 7.26; H ϵ 1 8.50 Cδ 119.93 Cϵ1 136.27 H γ 1.70/1.32; γCH_3 1.03 δCH_3 0.98 Cγ1 28.30 Cγ2 16.79 Cδ 12.22
8	Gln	8.47 N 120.70	4.03 59.13	2.14/2.11 28.91
9	Tyr	7.84 N 120.77	4.26 60.88	H δ 6.96; H ϵ 6.75; Cδ1 133.66 Cϵ1 117.77
10	Tyr	7.87 N 120.23.	4.29 60.82	3.26/3.22 38.11
11	Leu	8.34 N 119.99	4.04 57.26	1.99/1.91 41.69
12	Gln	7.81 N 118.28	4.11 57.58	2.01/1.91 28.81
13	Tyr	7.91 N 120.43	4.38 59.51	3.10/2.82 35.59
14	Lys	7.90 N 120.21	4.06 57.55	1.82/1.79 31.61
15	Asp	7.93 N 118.92	4.80 53.56	2.92/2.76 39.48
16	Leu	7.76 123.89	4.54 54.95	1.79 41.64
17	Pro		4.45 63.27	2.39/1.95 31.32
18	Val	7.74 N 120.40	3.79 65.07	2.17 31.81
19	Ser	8.02 N 116.85	4.23 60.48	3.99/3.95
20	Leu	7.82 N 122.93	4.36 56.20	1.77 41.96
21	Arg	7.77 N 120.34	4.20 57.49	1.93 30.15
22	Arg	8.05 N 121.00	4.28 57.05	1.89/1.85 30.14
23	Gly	8.00 N 109.07	3.95 45.43	
24	Ala	7.81 N 124.37	4.39 52.21	1.43 19.05
25	Asn	7.98 N 119.26	5.02 51.13	2.96/2.79 39.17
26	Pro		4.44 61.79	2.32/1.98 29.10

TABLE 1: Continued.

Residue	HN/N	Ha/Cα	Hβ/Cβ	Other
27 Gly	8.34 N 108.58	3.94 43.10		
28 Phe	7.83 N 122.56	4.50 56.50	3.15/3.13 36.59	Hδ 7.25; Hε 7.29; Hζ 7.18 Cδ 130.90/129.60 Cε 130.95/129.53 Cζ 131.21
29 His	8.05 N 119.37	4.44 54.41	3.32/3.25 25.86	Hδ2 7.31; Hε1 8.51 Cδ2 119.91 Cε1 139.03
30 Glu	8.15 N 121.57	4.23 54.73	2.15/2.10 24.95	γCH ₃ 2.45 Cγ 33.54
31 Ala	8.07 N 125.19	4.31 51.07	1.46 15.87	
32 Ile	7.76 N 118.79	4.06 61.44	1.83 35.60	Hγ 1.44/1.18; γCH ₃ 0.88; δCH ₃ 0.82 Cγ1 27.34 Cγ2 16.84 Cδ 12.08
33 Gly	7.96 N 110.69	3.95/3.87 43.26		
34 Asp	7.97 N 120.70	4.74 51.72	2.89 36.82	
35 Val	7.78 N 120.34	4.08 60.78	2.23 29.97	γCH ₃ 1.00 Cγ 20.31/24.50
36 Leu	7.82 N 122.65	4.40 52.58	1.72 39.65	Hγ 1.38; δCH ₃ 0.92/0.88 Cγ 27.26 Cδ 24.16/22.01
37 Ala	7.56 N 128.06	4.25 50.34	1.43 16.51	

backbone of both Zn²⁺-ACE peptides have been identified through the analysis of the TOCSY spectra (Figure 5). ¹H spin systems of the His, Phe and Tyr aromatic rings were identified with the combined use of [¹H-¹H]-TOCSY and NOESY spectra (Tables 1 and 2). The two proline residues existing in each construct were found to be at *trans* conformation for both peptides manifested by strong H_δ(i)Pro- H_α(i-1) NOE connectivities.

3.3. NMR Solution Models of Zn²⁺-ACE_N(37) & Zn²⁺-ACE_C(37) Peptides. As far as the N-terminal Zn-binding motif of ACE_N(37) peptide, which contains the two histidyl ligands, is concerned, no definite conformation could be determined due to conformational averaging. A 7-residue fragment close to the N-terminal (Gln⁸-Asp¹⁵) adopts helical structure, which consists partly of an α-helix for the 8-11 fragment and of a short ₃₁₀-helix for the rest of the four-residue segment. A second fragment comprised of 7 residues close to peptide C-terminal (His²⁹-Leu³⁶) adopts a well formed α-helical structure. As far as the intermediate fragment of the 23-residue spacer between the two binding motifs is concerned, no helical conformation has been identified. The proximity of the two “active sites helices” is manifested by long-range NOEs concerning backbone and side-chain protons of His²-Glu³⁰, Gly⁵-Gly³⁴, Tyr⁹-Phe²⁸ see (Figure S1) in Supplementary Material available online at doi: 10.1155/2010/820476, as well as Tyr⁹-His³⁰ (Figure 6).

The Zn²⁺-ACE_C(37) backbone is characterized by the high content of helical structure. Two helical conformations were observed at both N- and C-termini, spanning residues

His⁶-Lys¹⁴ and Phe²⁸-Val³⁵, respectively. Moreover, a ₃₁₀-helix comprised of a 5-residue segment (Ala¹⁹-Gly²³) has been identified for the intermediate fragment. In accordance with the Zn²⁺-ACE_N(37) peptide, the two zinc-binding motifs of Zn²⁺-ACE_C(37) are in spatial proximity as manifested by long-range NOEs, such as those between His⁶/Ile⁷ and His²⁹ as well as Gln⁸/Gln¹² with Ala¹⁹ (Figure 7).

3.4. Solution Structure of Zn²⁺-ACE_N(37) versus Zn²⁺-ACE_C(37). Although the overall fold of the two Zn²⁺-ACE peptides exhibits significant similarities, some striking differences, mainly related to the helical extent are detected (Figure 8). The double substitution of Tyr¹⁰ and Leu¹¹ in ACE_N(37) with Phe¹⁰ and Met¹¹ in ACE_C(37) does not impose any structural change, and the α-helix conformation of this segment remains. The nonhelical character of the N-terminal pentapeptide, which comprises the first Zn²⁺-binding motif, followed by a helical domain of eight to nine residues is conserved in both ACE peptides. However, small differences in NOEs are observed, regarding residues Ile⁷, Phe¹⁰/Tyr¹⁰, and Leu¹¹/Met¹¹ in ACE_N(37) and ACE_C(37) peptide, respectively. Because of the differentiation in position 10, the long range NOEs of the vicinal Tyr⁹ with Phe²⁸ and His²⁹ that are presented in ACE_N(37) peptide, are not detected in ACE_C(37). Furthermore, a long-range NOE between H_ε of Arg²¹ and H_ε of Phe²⁸ detected only in Zn²⁺-ACE_N(37) peptide suggests the existence of a loop with the two residues coming close to each other, confirming a tertiary slight structural difference among the two peptides in terms of the orientation of the two zinc-binding motif

TABLE 2: ^1H , ^{15}N , and ^{13}C chemical shifts (ppm) of the residues in the Zn^{2+} -ACE_C(37) peptide at 298K ($\text{H}_2\text{O}/\text{TFE}-d_2$ 34%/66% v/v. pH = 4.9).

Residue	HN/N	H α /C α	H β /C β	Other
1	His		4.44 55.45	H δ 2 7.34; H ϵ 1 8.48 Cδ2 120.14 Cϵ1 141.76
2	His	7.92 N 117.71	4.83 55.86	3.41/3.37 28.53 H δ 27.31; H ϵ 18.42 Cδ2 119.85 Cϵ1 136.29
3	Glu	8.44 N 121.00	4.47 56.93	2.15 31.82 γCH_3 2.64 Cγ 31.95
4	Met		4.30 58.52	2.12/2.06 33.59 H γ 2.44; Cγ 34.85
5	Gly	8.22 N 109.22	3.98 45.83	
6	His	8.22 N 119.42	4.69 57.33	3.39 28.64 H δ 27.25; H ϵ 1 8.50 Cδ2 119.79 Cϵ1 138.23
7	Ile	8.06 N 122.46	4.04 64.13	2.07 38.09 H γ 1.71/1.31; γCH_3 1.03 δCH_3 0.97 Cγ1 28.41 Cγ2 16.81 Cδ 12.18
8	Gln	8.44 N 121.01	4.08 59.04	2.15/2.11 28.57 H γ 2.42; δNH_2 6.54/7.13 Cγ 33.52 Nϵ2 110.83
9	Tyr	7.90 N 120.96	4.27 61.02	3.12 38.21 H δ 6.95; H ϵ 6.76 Cδ1 132.67 Cϵ1 117.74
10	Phe	8.07 N 120.42	4.37 60.74	3.33/3.26 38.84 H δ 7.31; H ϵ 7.37 H ζ 7.34 Cδ 131.03/129.50 Cϵ 131.00/129.43 Cζ 131.36
11	Met	8.43 N 118.65	4.21 57.43	2.23/2.15 33.58 H γ 2.79/2.72 Cγ 32.35
12	Gln	7.81 N 118.68	4.14 57.74	2.00/1.90 28.75 H γ 2.22/2.17; δNH_2 6.40/6.70 Cγ 33.50 Nϵ2 110.86
13	Tyr	7.92 N 120.02	4.38 59.46	3.13/2.82 39.33 H δ 7.00; H ϵ 6.74 Cδ 132.81 Cϵ 117.84
14	Lys	7.85 N 120.09	4.05 57.76	1.78/1.81 31.58 H γ 1.39; δCH_3 1.64; ϵCH_3 3.05 Cγ 23.68 Cδ 28.76 Cϵ 42.19
15	Asp	7.90 N 118.79	4.83 53.53	2.93/2.77 39.51
16	Leu	7.78 123.98	4.46 56.77	1.79 41.25 H γ 1.77; δCH_3 0.943/0.97 Cγ 26.83 Cδ 23.25/24.05
17	Pro		4.39 64.61	2.41/1.89 31.21 H γ 2.11/2.07; H δ 3.66/3.87 Cγ 26.79 Cδ 50.16
18	Val	7.60 N 120.40	3.68 65.47	2.17 31.77 γCH_3 1.07/0.98 Cγ 20.23/21.25
19	Ala	7.94 N 123.38	4.08 54.68	1.46 18.08
20	Leu	7.95 N 123.48	4.25 56.69	1.78 41.91 H γ 1.63; δCH_3 0.92/0.89 Cγ 27.43 Cδ 22.06/24.33
21	Arg	7.70 N 120.14	4.15 57.82	1.96 30.09 H γ 1.75/1.63; H δ 3.15; H ϵ 7.06 Cγ 26.80 Cδ 42.96 Nϵ 135.38
22	Glu	8.23 N 119.39	4.30 57.01	2.10/2.00 28.25 γCH_3 2.46/2.42 Cγ 33.01
23	Gly	7.95 N 108.22.	3.93 45.70	
24	Ala	7.78 N 123.97	4.40 52.25	1.45 18.47
25	Asn	7.90 N 118.78	5.03 51.01	3.03/2.81 39.09 δNH_2 6.61/7.50 Nδ2 113.04

TABLE 2: Continued.

Residue	HN/N	H α /C α	H β /C β	Other
26	Pro	4.45 64.33	2.35/2.01 31.50	H γ 2.07/2.02; H δ 3.91/3.85 C γ 26.84 C δ 50.43
27	Gly	8.34 N 108.27	3.94 45.73	
28	Phe	7.83 N 122.54	4.49 59.19	3.16 39.20 H δ 7.24; H ϵ 7.28; H ζ 7.15 C δ 130.90/129.43 C ϵ 130.94/129.55 C ζ 131.15
29	His	8.03 N 118.86	4.40 57.20	3.32/3.28 28.38 H δ 7.33; H ϵ 1 8.51 C δ 119.94 C ϵ 1 135.99
30	Glu	8.15 N 121.32	4.22 57.33	2.16/2.12 27.91 γ CH $_3$ 2.46 C γ 33.66
31	Ala	8.05 N 124.86	4.28 53.62	1.47 18.02
32	Ile	7.75 N 118.32	4.05 64.06	1.89 38.03 H γ 1.41/1.18; γ CH $_3$ 0.85; δ CH $_3$ 0.80 C γ 1 27.29 C γ 2 16.80 C δ 12.02
33	Gly	7.94 N 110.35	3.90/3.86 45.81	
34	Asp	7.97 N 120.63	4.74 54.30	2.88 39.45
35	Val	7.77 N 120.04	4.08 63.48	2.24 32.45 γ CH $_3$ 0.99 C γ 20.23/23.01
36	Leu	7.83 N 125.55	4.39 55.14	1.71 42.14 H γ 1.63; δ CH $_3$ 0.92/0.88 C γ 28.74 C δ 24.36/21.98
37	Ala	7.55 N 128.05	4.24 52.89	1.43 19.23

 FIGURE 6: (a) Ensemble of DYANA 30 best models of the Zn²⁺-ACE_N(37) (corresponds to His³⁶⁰-Ala³⁹⁶ of the human somatic form) calculated with NMR data. (b) Ribbon diagram of Zn²⁺-ACE_N(37) peptide.

 FIGURE 7: (a) Ensemble of DYANA 30 best models of the Zn²⁺-ACE_C(37) (corresponds to His⁹⁵⁸-Ala⁹⁹⁴ of the human somatic form), calculated with NMR data. (b) Ribbon diagram of Zn²⁺-ACE_C(37) peptide.

FIGURE 8: Backbone and ribbon representation of the solution structures of both Zn²⁺-ACE_N(37) (a) (corresponds to His³⁶⁰-Ala³⁹⁶ of the human somatic form) and Zn²⁺-ACE_C(37) (b) (corresponds to His⁹⁵⁸-Ala⁹⁹⁴ of the human somatic form).

FIGURE 9: Superimposition of the crystal structure (in red) and the solution structure derived from NMR data (in cyan) of Zn²⁺-ACE_N(37) peptide (a) and Zn²⁺-ACE_C(37) peptide (b).

helices. In ACE_C(37) peptide, the two side chains of these residues are oriented almost parallel to each other pointing though to opposite orientation providing a more “extended” conformation for this segment. Additionally, a helix of the C-termini is observed in both peptides.

The substitutions of the amino acids at positions 19 (Ser¹⁹/Ala¹⁹) and 22 (Arg²²/Glu²²) of the peptide sequence

seem to differentiate the structure of the two peptides. The most important diversity among the structures of the ACE_{N/C} peptides regards the 5-residue spanning α -helix (Ala¹⁹-Gly²³) of the intermediate spacer between the two zinc-binding motifs, detected only in the ACE_C(37) peptide. The absence of the intermediate helix in the ACE_N(37) peptide probably provides a less constrained domain to the

N-active site of the somatic form in a crucial socket region for the substrate binding. As a conclusion, the presence or absence of the helical structure of the intermediate spacer determines the relative position of the two terminal helices and differentiates the active-site cavity structure and volume, where the substrate is accommodated. Both active sites of the somatic form act as carboxy dipeptidase, hydrolyzing the amide bond and releasing the C-terminal dipeptide from a native substrate [1]. Additionally, only the ACE_N domain presents endopeptidase activity, by releasing the C-terminal tripeptide of the GnRH hormone and the tetrapeptide of the native octapeptide Enkephalin [12]. Accommodation of these peptides in active or not mode for proteolytic cleavage, might be influenced by the conformation of the interhelical spacer.

3.5. NMR Solution Structure versus X-Ray. The overall fold of both synthetic peptides solution structures presents high similarity to the corresponding domain of the crystal structure of the testis ACE isoform [19] (tACE has identical sequence with the C-domain of the ACE somatic isoform) and the somatic ACE_N domain [18]. Minor differences exist regarding the length of the helices at the termini of the peptides (Figure 9). The backbone RMSD value for the family of 20 NMR structures of the ACE_N peptide and the crystal structure (2C6F) was found to be 1.42 Å and the corresponding RMSD value calculated for the mean NMR structure and the X-ray structure was found to be 3.802 Å. The backbone RMSD value for the family of 20 NMR structures of the ACE_C peptide and the crystal structure (1O8A) was found to be 0.775 Å and the corresponding RMSD value calculated for the mean NMR structure and the X-ray structure was found to be 3.595 Å.

In the tACE X-ray structure, two helical fragments are present at the N- and C- terminal, both comprising a 12-residue segment (Figure 9). For ACE_N crystal structure the N-terminal 13-residue fragment exhibits a helical conformation, as well as the entire C-terminal 12-residue fragment (Figure 9(a)). Regarding the intermediate spacer among the two zinc-binding motifs, an additional helix region consisting of 3 amino acids is present at both tACE and ACE_N X-ray structures. In the case of the NMR derived structure, a shorter helical fragment has been observed for both termini. The obtained data for the Zn²⁺-ACE_N(37) suggest that as far as the N-terminal is concerned a 10-residue fragment (His⁶-Asp¹⁵) and as far as the C-terminal is concerned a 8-residue fragment (His²⁹-Leu³⁶) exhibit helical conformation. Similar results have been obtained for the synthetic peptide representing the C-catalytic domain of the human somatic form and the corresponding domain of the testis form. Differences among the ACE catalytic site maquettes and X-ray structures might be due to the fact that the native N- and C-domains exhibit compact structures, and packing of the structure elements in the interior of the enzyme where the catalytic center is cited diminishes the conformational flexibility of the two active-site helices.

Concerning the intermediate spacer between the two zinc-binding motifs, the X-ray models present an additive

3-residue helical segment residue, concerning residues 18-20 (numbering of crystal structure: tACE: Val³⁹⁹-Leu⁴⁰¹; ACE_N: Val³⁷⁷-Leu³⁷⁹). NMR solution structure of the Zn²⁺-ACE_C(37) peptide resulted in significantly similar conformation. At ACE_C(37) peptide, a ₃₁₀ helix is formed for the 5-residue segment Ala¹⁹-Gly²³. Instead, no helical conformation has been detected for the Zn²⁺-ACE_N(37) peptide, according to the NMR data and the DYANA calculations. However, both structures of tACE and sACE_N have been further solved in complex with the typical ACE inhibitor, lisinopril [19] (Figures S2 and S3). Among them, a helical structure is identified for the intermediate spacer only in the tACE-lisinopril structure, while in the sACE_N-lisinopril model the helical segment is absent. The modifications of positions 19 and 22 in the sACE_N peptide are probably playing an important role in the structural diversity of the spacer and are consequently crucial for the different activity and substrate specificity of these two active sites.

As a conclusion, the conformation of the synthetic peptides and the orientation of the two helical motifs upon zinc coordination are remarkably similar to the native structure, indicating the ACE catalytic site maquettes as reliable models of the enzyme active centre. The detected differences are clearly depended on the physicochemical properties of the peptides in solution compared to the crystal structures.

4. Conclusions

NMR studies of the synthetic peptides generated structures that successfully simulate the crystal structures of ACE C- and N-domains. Circular dichroism experiments provided important data, compensate not only for experimental conditions of the NMR analysis, but also for the elucidation of the structural characteristics of the two peptides, corresponding to the two somatic isoform ACE catalytic sites domains. The TFE use in aqueous mixtures, the proper pH value, as well as the presence of the Zn-ion create a solution environment, in which peptides adopt a similar fold to the native structure. The NMR data and the computational analysis led to structural models of the peptides, which are in great agreement with the X-ray structures. The secondary structure features of the peptides that correspond to the sequence of the ACE catalytic sites X-ray structures Zn²⁺-ACE_N(37) to ACE_N; Zn²⁺-ACE_C(37) to tACE present minor differences compared to the crystal structures. Furthermore, the ACE maquettes and the X-ray structures present significant similarities in the orientation of the active site helices, in respect of the position of the zinc ligands for metal coordination. On the other hand, the peptide representing the N-catalytic site lacks the helix of the intermediate region. Thus, the two terminal helices of the C-catalytic site maquette are found closer than those in ACE_N, illustrating potential differences into the catalytic site pocket for substrate selectivity, binding, and accommodation. This crucial difference might possibly explain the functional diversity of the two somatic isoforms of the human ACE. This approach might be helpful in the reconstitution of

other enzymes' active sites with unknown structures. In *gluzincins*, the spacer among the two zinc-binding motifs is regarded as of great importance for the specificity of the native substrates and external ligands, such as inhibitors. As far as somatic ACE is concerned, both active sites exhibit carboxy dipeptidase function while only the N-catalytic site exhibits also endopeptidase activity.

In the work reported here, crucial structural data for solution conformations have been extracted even though the crystal structure of testis ACE has been solved. Due to the functional diversity of the two ACE active sites, the "structure-based drug design" of the next generation of pharmaceutical agents, which specifically inhibit one of the two zinc catalytic domains of somatic ACE, is of major importance for the preferential modulation of ACE proteolytic activity towards a more effective treatment of hypertensive patients.

Abbreviations

ACE:	Angiotensin-I Converting Enzyme
sACE:	ACE somatic isoform
tACE:	ACE testis isoform
ACE _N :	N-domain of sACE
ACE _C :	C-domain of sACE
TFE:	2,2,2-trifluoroethanol
DQF-COSY:	Double-quantum-filtered phase-sensitive correlated spectroscopy
Tris:	Tris(hydroxymethyl)aminomethane
TOCSY:	Total Correlated Spectroscopy
NOE:	Nuclear Overhauser effect
NOESY:	Nuclear Overhauser effect spectroscopy
TPPI:	Time-proportional phase incrementation
WATERGATE:	Water suppression by gradient-tailored excitation
RMSD:	Root Mean Square Deviation
REM:	Restrained Energy Minimization
GPCRs:	G-protein coupled receptors.

Acknowledgments

G. A. Spyroulias and Z. Spyranti wish to thank EU-NMR program Grant RII3-026145 (Center of Magnetic Resonance no. (CERM), University of Florence) for access to NMR instrumentation. G. A. Spyroulias also acknowledges a short-term EMBO grant (ASTF 53.00-03). Z. Spyranti and A. S. Galanis contributed equally to this work. Dr. Maria Pelekanou is also acknowledged for assistance in CD measurements.

References

- [1] R. L. Soffer, "Angiotensin converting enzyme and the regulation of vasoactive peptides," *Annual Review of Biochemistry*, vol. 45, pp. 73–94, 1976.
- [2] E. G. Erdos, "Angiotensin I converting enzyme and the changes in our concepts through the years," *Hypertension*, vol. 16, no. 4, pp. 363–370, 1990.
- [3] H. Gavras, "Angiotensin converting enzyme inhibition and its impact on cardiovascular disease," *Circulation*, vol. 81, no. 1, pp. 381–388, 1990.
- [4] The Heart Outcomes Prevention Evaluation Study Investigators, "Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients," *New England Journal of Medicine*, vol. 342, pp. 145–153, 2000.
- [5] PEACE Trial Investigators, "Angiotensin-converting-enzyme inhibition in stable coronary artery disease," *New England Journal of Medicine*, vol. 351, no. 20, pp. 2058–2068, 2004.
- [6] T. Inagami, "The renin-angiotensin system," *Essays in Biochemistry*, vol. 28, pp. 147–164, 1994.
- [7] M. A. Ondetti and D. W. Cushman, "Enzymes of the renin-angiotensin system and their inhibitors," *Annual Review of Biochemistry*, vol. 51, pp. 283–308, 1982.
- [8] A. Roks, H. Buikema, Y. M. Pinto, and W. H. van Gilst, "The renin-angiotensin system and vascular function. The role of angiotensin II, angiotensin-converting enzyme, and alternative conversion of angiotensin I," *Heart and Vessels*, vol. 12, pp. 119–124, 1997.
- [9] P. Bunning, B. Holmquist, and J. F. Riordan, "Substrate specificity and kinetic characteristics of angiotensin converting enzyme," *Biochemistry*, vol. 22, no. 1, pp. 103–110, 1983.
- [10] M. R. W. Ehlers, E. A. Fox, D. J. Strydom, and J. F. Riordan, "Molecular cloning of human testicular angiotensin-converting enzyme: the testis isozyme is identical to the C-terminal half of endothelial angiotensin-converting enzyme," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 86, no. 20, pp. 7741–7745, 1989.
- [11] A.-L. Lattion, F. Soubrier, J. Allegrini, C. Hubert, P. Corvol, and F. Alhenc-Gelas, "The testicular transcripts of the angiotensin I-converting enzyme encodes for the ancestral, non-duplicated form of the enzyme," *FEBS Letters*, vol. 252, no. 1–2, pp. 99–104, 1989.
- [12] M. R. W. Ehlers and J. F. Riordan, "Angiotensin-converting enzyme: zinc- and inhibitor-binding stoichiometries of the somatic and testis isozymes," *Biochemistry*, vol. 30, no. 29, pp. 7118–7126, 1991.
- [13] M. J. Rieder, S. L. Taylor, A. G. Clark, and D. A. Nickerson, "Sequence variation in the human angiotensin converting enzyme," *Nature Genetics*, vol. 22, no. 1, pp. 59–62, 1999.
- [14] N. M. Hooper, "Families of zinc metalloproteases," *FEBS Letters*, vol. 354, no. 1, pp. 1–6, 1994.
- [15] G. A. Spyroulias, A. S. Galanis, G. Pairas, E. Manessi-Zoupa, and P. Cordopatis, "Structural features of angiotensin-I converting enzyme catalytic sites: conformation studies in solution, homology models and comparison with other zinc metallopeptidases," *Current Topics in Medicinal Chemistry*, vol. 4, no. 4, pp. 403–429, 2004.
- [16] A. S. Galanis, G. A. Spyroulias, R. Pierattelli, et al., "Zinc binding in peptide models of angiotensin-I converting enzyme active sites studied through ¹H-NMR and chemical shift perturbation mapping," *Biopolymers*, vol. 69, no. 2, pp. 244–252, 2003.
- [17] A. S. Galanis, G. A. Spyroulias, G. Pairas, E. Manessi-Zoupa, and P. Cordopatis, "Solid-phase synthesis and conformational properties of angiotensin converting enzyme catalytic-site peptides: the basis for a structural study on the enzyme-substrate interaction," *Biopolymers*, vol. 76, no. 6, pp. 512–526, 2004.
- [18] H. R. Corradi, S. L. U. Schwager, A. T. Nchinda, E. D. Sturrock, and K. R. Acharya, "Crystal structure of the N domain of

- human somatic angiotensin I-converting enzyme provides a structural basis for domain-specific inhibitor design," *Journal of Molecular Biology*, vol. 357, no. 3, pp. 964–974, 2006.
- [19] R. Natesh, S. L. U. Schwager, E. D. Sturrock, and K. R. Acharya, "Crystal structure of the human angiotensin-converting enzyme-lisinopril complex," *Nature*, vol. 421, no. 6922, pp. 551–554, 2003.
- [20] G. Bohm, R. Muhr, and R. Jaenicke, "Quantitative analysis of protein far UV circular dichroism spectra by neural networks," *Protein Engineering*, vol. 5, no. 3, pp. 191–195, 1992.
- [21] L. Braunschweiler and R. R. Ernst, "Coherence transfer by isotropic mixing: application to proton correlation spectroscopy," *Journal of Magnetic Resonance*, vol. 53, no. 3, pp. 521–528, 1983.
- [22] A. Bax and D. G. Davis, "MLEV-17-based two-dimensional homonuclear magnetization transfer spectroscopy," *Journal of Magnetic Resonance*, vol. 65, no. 2, pp. 355–360, 1985.
- [23] A. D. Bax and S. Grzesiek, "Methodological advances in protein NMR," *Accounts of Chemical Research*, vol. 26, no. 4, pp. 131–138, 1993.
- [24] A. G. Palmer III, J. Cavanagh, P. E. Wright, and M. Rance, "Sensitivity improvement in proton-detected two-dimensional heteronuclear correlation NMR spectroscopy," *Journal of Magnetic Resonance*, vol. 93, no. 1, pp. 151–170, 1991.
- [25] D. Marion and K. Wüthrich, "Application of phase sensitive two-dimensional correlated spectroscopy (COSY) for measurements of ^1H - ^1H spin-spin coupling constants in proteins," *Biochemical and Biophysical Research Communications*, vol. 113, no. 3, pp. 967–974, 1983.
- [26] J. Jeener, B. H. Meier, P. Bachmann, and R. R. Ernst, "Investigation of exchange processes by two-dimensional NMR spectroscopy," *Journal of Chemical Physics*, vol. 71, no. 11, pp. 4546–4553, 1979.
- [27] C. Eccles, P. Güntert, M. Billeter, and K. Wüthrich, "Efficient analysis of protein 2D NMR spectra using the software package EASY," *Journal of Biomolecular NMR*, vol. 1, no. 2, pp. 111–130, 1991.
- [28] P. Güntert, W. Braun, and K. Wüthrich, "Efficient computation of three-dimensional protein structures in solution from nuclear magnetic resonance data using the program DIANA and the supporting programs CALIBA, HABAS and GLOMSA," *Journal of Molecular Biology*, vol. 217, no. 3, pp. 517–530, 1991.
- [29] P. Güntert, C. Mumenthaler, and K. Wüthrich, "Torsion angle dynamics for NMR structure calculation with the new program DYANA," *Journal of Molecular Biology*, vol. 273, no. 1, pp. 283–298, 1997.
- [30] K. Wüthrich, M. Billeter, and W. Braun, "Pseudo-structures for the 20 common amino acids for use in studies of protein conformations by measurements of intramolecular proton-proton distance constraints with nuclear magnetic resonance," *Journal of Molecular Biology*, vol. 169, no. 4, pp. 949–961, 1983.